Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

National Cancer Institute Making More Taxol Available for Refractory Ovarian, Breast Cancers

National Cancer Institute Making More Taxol Available for Refractory Ovarian, Breast Cancers TAXOL (Bristol-Myers Squibb Company, Princeton, NJ) is becoming more available to women with refractory ovarian carcinoma, National Cancer Institute officials say. Oncologists can apply to the Bethesda, Md, institute for the experimental anticancer drug and protocol for administering it. In addition, these officials say, the institute plans to expand its Treatment Referral Center program to provide the drug to physicians treating patients with advanced, refractory breast cancer. However, the institute says, "it is by no means clear that Taxol is the best treatment for these women," and it "strongly recommends that eligible breast cancer patients discuss with their physicians whether Taxol, standard treatments, or other clinical trials are most appropriate for them." In the case of the expanded access to the drug this fall for physicians treating refractory ovarian cancer, institute officials say that this reflects increased supplies of the drug, "indications in ongoing clinical trials of its effectiveness in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

National Cancer Institute Making More Taxol Available for Refractory Ovarian, Breast Cancers

Gunby, Phil
JAMA , Volume 268 (14) – Oct 14, 1992
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/national-cancer-institute-making-more-taxol-available-for-refractory-pygP5aGO6D

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1992 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1992.03490140028008
Publisher site
See Article on Publisher Site

Abstract

TAXOL (Bristol-Myers Squibb Company, Princeton, NJ) is becoming more available to women with refractory ovarian carcinoma, National Cancer Institute officials say. Oncologists can apply to the Bethesda, Md, institute for the experimental anticancer drug and protocol for administering it. In addition, these officials say, the institute plans to expand its Treatment Referral Center program to provide the drug to physicians treating patients with advanced, refractory breast cancer. However, the institute says, "it is by no means clear that Taxol is the best treatment for these women," and it "strongly recommends that eligible breast cancer patients discuss with their physicians whether Taxol, standard treatments, or other clinical trials are most appropriate for them." In the case of the expanded access to the drug this fall for physicians treating refractory ovarian cancer, institute officials say that this reflects increased supplies of the drug, "indications in ongoing clinical trials of its effectiveness in

Journal

JAMA – American Medical Association

Published: Oct 14, 1992

There are no references for this article.